We are live on ! Find out more
GTHX

G1 Therapeutics, Inc. Common Stock

Delisted

GTHX was delisted on the 17th of September, 2024.

118 hedge funds and large institutions have $336M invested in G1 Therapeutics, Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 39 increasing their positions, 29 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

271% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 7

34% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 29

18% more funds holding

Funds holding: 100118 (+18)

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

52% less capital invested

Capital invested by funds: $699M → $336M (-$362M)

100% less call options, than puts

Call options by funds: $2K | Put options by funds: $1.76M

Holders
118
Holders Change
+18
Holders Change %
+18%
% of All Funds
2.38%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
26
Increased
39
Reduced
29
Closed
7
Calls
$2K
Puts
$1.76M
Net Calls
-$1.76M
Net Calls Change
-$1.72M
Name Holding Trade Value Shares
Change
Change in
Stake
Two Sigma Investments
26
Two Sigma Investments
New York
$1.89M +$2.7M +163,310 New
Morgan Stanley
27
Morgan Stanley
New York
$1.62M +$1.61M +97,354 +226%
Bank of New York Mellon
28
Bank of New York Mellon
New York
$1.62M -$13.3K -806 -0.6%
PP
29
PDT Partners
New York
$1.62M +$1.63M +99,005 +242%
Los Angeles Capital Management
30
Los Angeles Capital Management
California
$1.61M +$302K +18,291 +15%
Jacobs Levy Equity Management
31
Jacobs Levy Equity Management
New Jersey
$1.42M +$1.11M +67,041 +119%
Two Sigma Advisers
32
Two Sigma Advisers
New York
$1.26M -$89.1K -5,400 -5%
Squarepoint
33
Squarepoint
New York
$1.21M +$1.38M +83,308 +394%
AIM
34
Aigen Investment Management
New York
$1.05M +$1.5M +90,985 New
CS
35
Credit Suisse
Switzerland
$1.01M +$694K +42,057 +92%
CA
36
CHI Advisors
New York
$970K +$660K +40,000 +91%
TI
37
Trexquant Investment
Connecticut
$897K +$1.28M +77,670 New
Ameriprise
38
Ameriprise
Minnesota
$832K -$115K -6,952 -9%
California Public Employees Retirement System
39
California Public Employees Retirement System
California
$818K +$29.7K +1,800 +3%
Rafferty Asset Management
40
Rafferty Asset Management
New York
$792K +$935K +56,675 +476%
Man Group
41
Man Group
United Kingdom
$734K +$1.05M +63,549 New
Swiss National Bank
42
Swiss National Bank
Switzerland
$729K
SG Americas Securities
43
SG Americas Securities
New York
$696K +$711K +43,076 +251%
Massachusetts Financial Services
44
Massachusetts Financial Services
Massachusetts
$641K +$915K +55,458 New
Susquehanna International Group
45
Susquehanna International Group
Pennsylvania
$640K +$633K +38,358 +226%
State of Wisconsin Investment Board
46
State of Wisconsin Investment Board
Wisconsin
$606K
RJFSA
47
Raymond James Financial Services Advisors
Florida
$596K +$256K +15,498 +43%
California State Teachers Retirement System (CalSTRS)
48
California State Teachers Retirement System (CalSTRS)
California
$595K +$7.41K +449 +0.9%
AA
49
ALPS Advisors
Colorado
$560K -$49.6K -3,002 -6%
EGM
50
Engineers Gate Manager
New York
$558K +$797K +48,297 New

GTHX Hedge Fund Activity: Q3 2020 in Review

118 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in G1 Therapeutics, Inc. Common Stock (GTHX) for Q3 2020, worth a combined $336M — down 52% from $699M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new GTHX positions and 7 closed out — a net gain of 19 holders — while 39 added to existing stakes and 29 trimmed.

The largest buyer was State Street, adding an estimated $16.6M. The largest seller was Fidelity Investments, cutting an estimated $22.6M.

  • 118 institutional investors held G1 Therapeutics, Inc. Common Stock (GTHX) as of Q3 2020, up from 100 in Q2 2020.
  • Funds reported $336M of G1 Therapeutics, Inc. Common Stock stock for Q3 2020, down 52% quarter-over-quarter.
  • 26 funds opened new G1 Therapeutics, Inc. Common Stock positions in Q3 2020 and 7 closed out, a net change of +19 holders.
  • The largest G1 Therapeutics, Inc. Common Stock buyer in Q3 2020 was State Street, an estimated $16.6M added.
  • The largest G1 Therapeutics, Inc. Common Stock seller in Q3 2020 was Fidelity Investments, an estimated $22.6M sold.

Based on aggregated 13F filings for Q3 2020.